Skip to main content
. 2010 Aug 9;4(4):732–740. doi: 10.1007/s12072-010-9208-0

Table 5.

Comparison of frequency of dose reduction of Peg-IFN, early termination, and SAEs in patients with CHB versus CHC

24-week group, n/N P 48-week group, n/N P
CHB CHC CHB CHC
Dose reduction and early termination 3/31 (9.7%) 7/57 (12.3%) 1.000 5/25 (20.0%) 6/46 (13.0%) 0.501
Early termination 0/31 (0.0%) 2/57 (3.5%) 0.538 1/25 (4.0%) 4/46 (8.7%) 0.650
SAEs 0/31 (0.0%) 3/57 (5.3%) 0.549 1/25 (4.0%) 4/46 (8.7%) 0.650

SAEs severe adverse events